IceCure Medical Says FDA Has At This Time Denied Its De Novo Classification Request For Breast Cancer Which Was Submitted Based On Interim Analysis From Its ICE3 Study
Portfolio Pulse from Benzinga Newsdesk
IceCure Medical's De Novo classification request for breast cancer, based on interim analysis from its ICE3 study, has been denied by the FDA at this time.
September 20, 2023 | 11:03 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The FDA's denial of IceCure Medical's De Novo classification request for breast cancer could negatively impact the company's stock in the short term.
The FDA's denial of IceCure's De Novo classification request is a significant setback for the company. This could lead to a negative investor sentiment, potentially causing a drop in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100